Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate
Ratio Therapeutics has entered into an exclusive worldwide license and collaboration agreement with Novartis Pharma AG to develop a Somatostatin Receptor 2 (SSTR2) radiotherapeutic candidate for cancer treatment. Under the agreement, Ratio will receive upfront and potential milestone payments totaling up to $745 million, plus tiered royalties. Ratio will collaborate on preclinical activities and candidate selection, while Novartis will handle subsequent development, manufacturing, and commercialization. The partnership aims to leverage Ratio's radioligand therapy expertise and technology platforms to develop best-in-class therapy for SSTR2-expressing tumors.
Ratio Therapeutics ha firmato un accordo esclusivo di licenza mondiale e collaborazione con Novartis Pharma AG per sviluppare un candidato radioterapeutico per il trattamento del cancro, specificamente un recettore della somatostatina 2 (SSTR2). In base all'accordo, Ratio riceverà pagamenti anticipati e potenziali pagamenti per traguardi per un totale fino a $745 milioni, oltre a royalties scaglionate. Ratio collaborerà su attività precliniche e sulla selezione dei candidati, mentre Novartis si occuperà dello sviluppo successivo, della produzione e della commercializzazione. L'obiettivo della partnership è sfruttare l'esperienza di Ratio nella terapia con radioligandi e le piattaforme tecnologiche per sviluppare una terapia di prima classe per i tumori che esprimono SSTR2.
Ratio Therapeutics ha firmado un acuerdo exclusivo de licencia mundial y colaboración con Novartis Pharma AG para desarrollar un candidato radioterapéutico del receptor de somatostatina 2 (SSTR2) para el tratamiento del cáncer. Según el acuerdo, Ratio recibirá pagos iniciales y potenciales pagos por hitos por un total de hasta $745 millones, además de regalías escalonadas. Ratio colaborará en actividades preclínicas y selección de candidatos, mientras que Novartis se encargará del desarrollo posterior, fabricación y comercialización. La asociación tiene como objetivo aprovechar la experiencia de Ratio en terapia con radioligandos y plataformas tecnológicas para desarrollar una terapia de primera clase para tumores que expresan SSTR2.
Ratio Therapeutics는 Novartis Pharma AG와 전세계 독점 라이센스 및 협력 협약을 체결하여 암 치료를 위한 소마토스타틴 수용체 2(SSTR2) 방사성 치료 후보 물질을 개발합니다. 이 협약에 따라 Ratio는 최대 $745 백만 달러의 선불 및 잠재적인 이정표 지급을 받을 것이며, 단계별 로열티도 포함됩니다. Ratio는 전임상 활동 및 후보 선택에 협력하고, Novartis는 이후 개발, 제조 및 상업화를 담당합니다. 이 파트너십은 Ratio의 방사성 리간드 요법 전문성과 기술 플랫폼을 활용하여 SSTR2를 발현하는 종양을 위한 최상의 치료제를 개발하는 것을 목표로 합니다.
Ratio Therapeutics a conclu un accord de licence mondiale exclusif et de collaboration avec Novartis Pharma AG pour développer un candidat radiothérapeutique ciblant le récepteur de la somatostatine 2 (SSTR2) pour le traitement du cancer. En vertu de cet accord, Ratio recevra des paiements initiaux et des paiements potentiels liés aux jalons totalisant jusqu'à 745 millions de dollars, ainsi que des redevances échelonnées. Ratio collaborera sur les activités précliniques et la sélection des candidats, tandis que Novartis s'occupera du développement ultérieur, de la fabrication et de la commercialisation. L'objectif de ce partenariat est de tirer parti de l'expertise de Ratio en thérapie par radioligand et de ses plateformes technologiques pour développer une thérapie de pointe pour les tumeurs exprimant SSTR2.
Ratio Therapeutics hat eine exklusive weltweite Lizenz- und Kooperationsvereinbarung mit Novartis Pharma AG geschlossen, um einen radiotherapeutischen Kandidaten für den Somatostatinrezeptor 2 (SSTR2) zur Krebsbehandlung zu entwickeln. Im Rahmen der Vereinbarung erhält Ratio Vorauszahlungen und potenzielle Meilensteinzahlungen in Höhe von bis zu 745 Millionen US-Dollar, sowie gestaffelte Lizenzgebühren. Ratio wird an präklinischen Aktivitäten und der Auswahl von Kandidaten mitwirken, während Novartis die anschließende Entwicklung, Herstellung und Vermarktung übernimmt. Das Ziel der Partnerschaft ist es, Ratios Expertise in der Radioligandentherapie und die technologischen Plattformen zu nutzen, um eine erstklassige Therapie für SSTR2-exprimierende Tumoren zu entwickeln.
- Significant deal value of up to $745 million in combined upfront and milestone payments
- Additional revenue potential through tiered royalty payments
- Partnership with major pharmaceutical company Novartis enhances development capabilities
- Risk reduction as Novartis assumes responsibility for development, manufacturing, and commercialization costs
- Early-stage preclinical candidate with uncertain development outcomes
- Milestone payments dependent on achieving development goals
Insights
This strategic licensing deal represents a significant milestone for Novartis in expanding its radioligand therapy (RLT) portfolio. The
The collaboration leverages Ratio's expertise in radiopharmaceutical development while utilizing Novartis's established commercial infrastructure and clinical development capabilities. This strategic fit could accelerate the development timeline and potentially lead to a best-in-class therapy. For Novartis shareholders, this represents a calculated investment in a growing therapeutic area where the company already has market presence and expertise.
The development of next-generation SSTR2-targeting therapeutics could significantly improve treatment options for patients with neuroendocrine tumors. Current SSTR2-targeted therapies have shown promise, but there's room for improvement in efficacy and safety profiles. Novartis's existing expertise in this space, combined with Ratio's innovative technology platforms, creates a strong foundation for developing potentially superior treatments.
The collaboration structure, where Ratio handles early-stage development before transitioning to Novartis for later stages, optimizes the strengths of both companies. This approach could lead to faster development timelines and better clinical outcomes, ultimately benefiting both patients and investors.
"The team at
"Radioligand therapies hold transformative potential for certain forms of cancer, and Novartis is committed to maximizing their impact by continually improving the benefit for patients," said Fiona Marshall, President of Biomedical Research at Novartis. "We are delighted to collaborate with
Under the terms of the agreement,
The collaboration combines the expertise and strengths of
Chestnut Partners served as exclusive financial advisor to
About Ratio Therapeutics
Ratio Therapeutics Inc. is a clinical-stage pharmaceutical company with the mission to accelerate the development of next-generation precision radiopharmaceuticals for solid tumors and transform oncology treatment paradigms. With headquarters and laboratories in Boston, the company currently employs a growing team of multidisciplinary experts with backgrounds in radiopharmaceutical discovery and development.
Please visit www.ratiotx.com for more information and follow us on Twitter (X) and LinkedIn.
Media Contacts:
Rachelle Babb, Ph.D.
Russo Partners, LLC
rachelle.babb@russopartnersllc.com
+1 (929) 325-7559
View original content to download multimedia:https://www.prnewswire.com/news-releases/ratio-enters-license-and-collaboration-agreement-with-novartis-for-sstr2-targeting-radiotherapeutic-candidate-302307509.html
SOURCE Ratio Therapeutics Inc.
FAQ
What is the value of the Ratio-Novartis (NVS) licensing agreement?
What is the focus of the Ratio-Novartis (NVS) collaboration agreement?
What are Novartis's (NVS) responsibilities in the Ratio collaboration?
When was the Ratio-Novartis (NVS) collaboration agreement announced?
